2003
DOI: 10.1016/s0264-410x(03)00002-1
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of recombinant sialoglycoprotease in protection of cattle against pneumonic challenge with Mannheimia (Pasteurella) haemolytica A1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
14
0
1

Year Published

2004
2004
2020
2020

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(16 citation statements)
references
References 23 publications
0
14
0
1
Order By: Relevance
“…M. haemolytica vaccines have traditionally been tested using one to two doses of vaccine with intratracheal, intrabronchial, or transthoracic challenge approximately 14 days after the last vaccination (12,39). Clinical signs are usually evaluated and cattle are euthanized and necropsied 4 to 6 days after challenge, with lung lesions quantified and compared to lesions in nonvaccinates.…”
Section: Discussionmentioning
confidence: 99%
“…M. haemolytica vaccines have traditionally been tested using one to two doses of vaccine with intratracheal, intrabronchial, or transthoracic challenge approximately 14 days after the last vaccination (12,39). Clinical signs are usually evaluated and cattle are euthanized and necropsied 4 to 6 days after challenge, with lung lesions quantified and compared to lesions in nonvaccinates.…”
Section: Discussionmentioning
confidence: 99%
“…These include live M. haemolytica (2,6,7,9,11,19,21,33,50), killed M. haemolytica cells (10,20,22,23,52), components or fractions of M. haemolytica cells (17,24,27,28,35,49,(53)(54)(55), and commercial vaccines (57,58). While immunity to M. haemolytica appears to require anti-LKT and antisurface antigen antibodies (55), partial protection could be afforded to cattle experimentally vaccinated with M. haemolytica preparations that did not contain LKT (21,40).…”
Section: Discussionmentioning
confidence: 99%
“…[23][24][25][26][27] In addition, three terminal studies (five trials) investigated the use of commercially available vaccines in feedlot cattle with a pathogen-challenged disease model [14,28,29], three studies (five trials) utilized dairy or beef calves with naturally occurring disease to investigate effects of vaccination [27,30,31], and thirteen studies investigated the use of commercially available vaccines in dairy calves with an induced-disease model. [32][33][34][35][36][37][38][39][40][41][42][43][44] Studies were excluded from the review: if they did not report original data (primary study), if they did not include a non-vaccinated/placebo control group, if the outcome did not include an assessment of morbidity risk, mortality risk, or extent of lung involvement (e.g. only reported serologic titers), or if the same results were published in a more complete form elsewhere.…”
Section: Methodsmentioning
confidence: 99%